# An Clinical Study of NKG2D-CAR-NK Cells for the Treatment of Refractory Recurrent Multiple Myeloma

> **NCT06379451** · EARLY_PHASE1 · UNKNOWN · sponsor: **Changzhou No.2 People's Hospital** · enrollment: 9 (estimated)

## Conditions studied

- Multiple Myeloma

## Interventions

- **DRUG:** NKG2D Chimeric Antigen Receptor NK Cell Injection

## Key facts

- **NCT ID:** NCT06379451
- **Lead sponsor:** Changzhou No.2 People's Hospital
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2024-04-18
- **Primary completion:** 2025-12-31
- **Final completion:** 2025-12-31
- **Target enrollment:** 9 (ESTIMATED)
- **Last updated:** 2024-04-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06379451

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06379451, "An Clinical Study of NKG2D-CAR-NK Cells for the Treatment of Refractory Recurrent Multiple Myeloma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06379451. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*